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AbsTrACT
Objective this phase ii, randomised, double-blind, 
placebo-controlled clinical trial was designed to evaluate 
the efficacy and safety of PF-00547659, a fully human 
monoclonal antibody that binds to human mucosal 
addressin cell adhesion molecule (MadcaM) to selectively 
reduce lymphocyte homing to the intestinal tract, in 
patients with moderate-to-severe crohn’s disease (cD).
Design eligible adults were aged 18–75 years, with 
active moderate-to-severe cD (crohn’s Disease activity 
index (cDai) 220–450), a history of failure or intolerance 
to antitumour necrosis factor and/or immunosuppressive 
agents, high-sensitivity c reactive protein >3.0 mg/l 
and ulcers on colonoscopy. Patients were randomised 
to PF-00547659 22.5 mg, 75 mg or 225 mg or placebo. 
the primary endpoint was cDai 70-point decrease from 
baseline (cDai-70) at week 8 or 12.
results in all, 265 patients were eligible for study entry. 
although cDai-70 response was not significantly different 
with placebo versus PF-00547659 treatment at weeks 8 
or 12, remission rate was greater in patients with higher 
baseline c reactive protein (>5 mg/l vs >18.8 mg/l, 
respectively). Soluble MadcaM decreased significantly 
from baseline to week 2 in a dose-related manner 
and remained low during the study in PF-00547659-
treated patients. circulating β7+ cD4+ central memory 
t-lymphocytes increased at weeks 8 and 12 with PF-
00547659 treatment. no safety signal was seen.
Conclusions clinical endpoint differences between PF-
00547659 and placebo did not reach statistical significance 
in patients with moderate-to-severe cD. PF-00547659 was 
pharmacologically active, as shown by a sustained dose-
related decrease in soluble MadcaM and a dose-related 
increase in circulating β7+ central memory t cells.
Trial registration number nct01276509; results.
InTrODuCTIOn
Crohn’s disease (CD) is a chronic, transmural 
inflammatory disease of the gastrointestinal 
tract.1 It follows a relapsing and remitting disease 
course, but a majority of patients eventually 
progress to complications of stricture, fistula and 
abscess.2 Patients with moderate-to-severe CD 
who do not respond to conventional therapy with 
steroids or immunosuppressive therapy (azathio-
prine, 6-mercaptopurine, methotrexate)3 are often 
treated with biologic therapy, including anti-tumour 
significance of this study
What is already known on this subject?
 ► Crohn’s disease (CD) is an inflammatory bowel 
disease that is often not adequately controlled 
using current treatments.
 ► Monoclonal antibodies that bind to integrins 
on lymphocytes and prevent their translocation 
can improve outcome in CD.
 ► Inhibition of the mucosal addressin cell 
adhesion molecule (MAdCAM) limb at the 
endothelial surface of the α4β7-MAdCAM 
translocation system, which is responsible 
for efficient trafficking and retention of 
leucocytes in the intestine, increases circulating 
β7 + memory T lymphocytes in animals.
 ► High placebo response rates in the Crohn’s 
Disease Activity Index endpoint can confound 
clinical trials in CD.
What are the new findings?
 ► PF-00547659 did not meet the primary 
endpoint of clinical response in moderate-to-
severe CD when compared with placebo.
 ► In patients with greater evidence of 
inflammation by high-sensitivity C reactive 
protein or Simple Endoscopic Activity Score, 
posthoc analyses suggested the presence of a 
drug effect.
 ► The human, anti-MAdCAM monoclonal 
antibody PF-00547659 was pharmacologically 
active, as shown by increased circulating β7+ 
central memory lymphocytes.
How might it impact on clinical practice in the 
foreseeable future?
 ► Future clinical trials that address regression 
to the mean and identify patients with more 
evidence of inflammation are needed to 
determine the role of anti-MAdCAM therapy in 
the treatment of CD.
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necrosis factor (TNF) antibodies (infliximab, adalimumab, 
certolizumab pegol)4 and, more recently, anti-interleukin-12/23 
monoclonal antibody (ustekinumab)5 and anti-α4β7 integrin anti-
body (vedolizumab),6 to induce and maintain clinical response 
and remission. However, patients who initially respond to 
anti-TNF or anti-integrin therapy can experience secondary 
loss of response, which is often resolved by switching to a drug 
within the same class.7 In addition, concerns remain about the 
safety of corticosteroid, immunosuppressive and anti-TNF ther-
apies. Thus, additional biological therapies would have clinical 
value.
Mucosal addressin cell adhesion molecule (MAdCAM) is 
expressed predominantly on the cell surface of high endothelial 
venules of organised intestinal lymphoid tissue, such as Peyer’s 
patches and mesenteric lymph nodes.8–10 It is not constitutively 
expressed in the central nervous system.11 MAdCAM plays a role 
in gut immune surveillance and also appears to facilitate exces-
sive lymphocyte infiltration under conditions of chronic gastro-
intestinal inflammation.8–10 The α4β7 integrin is the recognised 
ligand for MAdCAM, and its expression on populations of 
CD4+ and CD8+ T cells—as well as on subsets of B cells—
distinguishes it as a unique gut-homing lymphocyte. Selective 
inhibition of the interaction between MAdCAM and the α4β7 
integrin appears to avoid the risk of central nervous system 
infections associated with the non-selective blockade of α4 integ-
rins.12 13 Anti-α4β7 integrin antibody therapy with vedolizumab is 
effective for induction and maintenance of clinical remission in 
CD and no cases of progressive multifocal leukoencephalopathy 
have been reported with this treatment.6
PF-00547659 is a fully human monoclonal antibody that is 
expected to reduce gastrointestinal inflammation by binding to 
human MAdCAM and selectively reducing lymphocyte homing 
to the gut.14 The current phase II, dose-ranging, clinical trial was 
designed to evaluate the efficacy and safety of PF-00547659 
in patients with moderate-to-severe CD who have a history of 




This multicentre, randomised, double-blind, placebo-controlled, 
parallel-group trial was conducted at 103 centres in 15 coun-
tries (Austria, Belgium, Canada, France, Germany, Japan, Neth-
erlands, Norway, Poland, Serbia, Slovakia, South Africa, South 
Korea, Spain, USA), beginning in April 2011 and was completed 
in October 2015. The protocol was approved by the institu-
tional review board or ethics committee at each centre. (Protocol 
amendment information is provided in the online supplementary 
text.) All patients gave written, informed consent. All authors 
had access to study data and have reviewed and approved the 
final report. The study is registered on  ClinicalTrials. gov (NCT 
01276509).
Eligible patients were aged 18–75 years with moderate-to-se-
vere ileal (terminal ileum), ileocolonic or colonic CD (Crohn’s 
Disease Activity Index (CDAI) score 220–450 and ulcers on 
colonoscopy performed and interpreted locally at the study 
site during or within 8 weeks prior to screening).15 Patients 
had failed or were intolerant to immunosuppressive therapies 
(ie, azathioprine, 6-mercaptopurine, or methotrexate) and/or 
anti-TNF agents and had a high-sensitivity C reactive protein 
(hsCRP) concentration >3.0 mg/L (the upper limit of normal) at 
the central laboratory. (Definitions of treatment failure and intol-
erance are provided in the online supplementary text.) Patients 
were excluded if they had received >20 mg/day prednisone or 
equivalent oral systemic corticosteroid dose within 2 weeks 
prior to randomisation, >6 mg/day oral budesonide within 2 
weeks prior to randomisation or other biologics, including any 
anti-TNF agents, within 6 weeks from baseline/randomisation.
study design
Eligible patients were randomly assigned in a 1:1:1:1 ratio 
and double-blind fashion to receive placebo or PF-00547659 
22.5 mg, 75 mg or 225 mg (Pfizer, New York, New York, USA), 
administered by subcutaneous blinded injection at weeks 0, 4 
and 8 and were followed through week 12. Randomisation was 
performed centrally according to a computer-generated scheme. 
Stratification factors were the status of treatment failure with 
or intolerance to immunosuppressive/anti-TNF therapies and 
concomitant immunosuppressive therapy type. Stable doses 
of azathioprine, 6-mercaptopurine and methotrexate were 
continued from screening through week 8; beginning at week 8, 
dosages of these prior immunosuppressive agents were tapered 
by approximately 25% per week so that the agents were discon-
tinued by week 12. Doses up to 20 mg/day of prednisone (or 
equivalent) were permitted; no dose modification was allowed.
efficacy and safety assessments
Patients were evaluated at weeks 0 (baseline), 2, 4, 6, 8, 10 and 
12 (or at the withdrawal visit). At each visit, electronic diary-
card data were collected, a clinical assessment of CD and a phys-
ical examination were carried out, disease activity measured 
by CDAI, adverse events (AEs) and concomitant medications 
reported and samples taken for laboratory analysis. At each visit, 
patients underwent neurological assessment, which consisted of 
five tests: confrontational visual fields, timed 25-foot walk, nine-
hole peg test, symbol-digit modality test and Multiple Sclerosis 
Neuropsychological Questionnaire. Neurology consultation was 
requested if significant unexplained changes were observed.
Pharmacokinetics and antidrug antibodies (ADA)
Blood samples for the assessment of PF-00547659 concentra-
tions were collected and analysed at specified time points for the 
duration of the study using a validated assay. Analysis of ADA 
was conducted on serum samples using a multitiered approach, 
including screening assay, confirmatory assay and neutralising 
antibody assay. A positive anti-PF-00547659 antibody level was 
predefined as ≥4.64, independent of change from baseline, on 
at least one visit.
efficacy evaluations and statistical analysis
The primary efficacy outcome was the proportion of patients 
who achieved a CDAI-70 clinical response (ie, a decrease from 
baseline in CDAI ≥70 points) at week 8 or week 12. The two 
time points were selected due to concerns about a potential 
increase in disease activity resulting from withdrawal of immu-
nosuppressive therapy beginning at week 8. Secondary efficacy 
outcomes measured at all visits included the proportion of 
patients achieving CDAI-70 response, CDAI-100 response (ie, a 
decrease from baseline in CDAI ≥100 points), CDAI remission 
(ie, CDAI <150) and mean change from baseline in total CDAI.
Longitudinal data were analysed for both primary (CDAI-70 
response) and key secondary (CDAI-100 response and CDAI 
remission) endpoints using a generalised linear mixed-effect 
model (GLIMMIX) with subject as a random effect; treatment, 
visit and visit-by-treatment interaction as fixed effects and 
previous status of treatment failure or intolerance to anti-TNF-α 
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agents or immunosuppressive therapies, concomitant immuno-
suppressive therapy and baseline CDAI score as covariates. The 
GLIMMIX procedure incorporated the correlation between 
observations by modelling the random effects. The estimates 
(and SE) of each dose comparison with placebo were reported. 
For the CDAI-70 response endpoint, each dose for comparison 
of the Hochberg method was used to account for rejection of 
the null hypothesis if a treatment effect was detected at either 
of the two time points (week 8 or week 12). Because the CDAI-
70, CDAI-100 and CDAI remission data were modelled, model 
estimates are reported along with the SEs. Change from baseline 
in CDAI was also analysed longitudinally, using a mixed-model 
repeated measures analysis of the data and the same variables 
as the GLIMMIX model. This model was used to estimate the 
difference between each dose and placebo at all postbaseline 
visits (week 2 through week 12). The family-wise error rate is 
controlled at one-sided 0.05 using the Bonferroni method for 
two time points (week 8 or week 12). Because this was a phase 
II study, the family-wise error rate was controlled at 5% rather 
than at the 2.5% that is typically used for phase III studies.
Posthoc analyses were performed to assess CDAI-70 response 
and CDAI remission in subgroups of patients with baseline hsCRP 
concentrations>5.0 mg/L and >18.8 mg/L (median) and patients 
with baseline median Simple Endoscopic Activity Score–Crohn’s 
Disease (SES-CD)16 >10 (25th percentile) and >17 (median). 
In most patients, the SES-CD was calculated using data from 
endoscopies performed at baseline; in patients who underwent 
endoscopy 8 weeks prior to randomisation, the SES-CD score 
was calculated using data from that procedure.
Other secondary outcomes were faecal calprotectin, hsCRP 
concentrations, β7+ central memory CD4+ T cells, soluble 
MAdCAM and mean change from baseline in these concentra-
tions at weeks 4, 8 and 12 and PF-00547659 concentration by 
visit. The proportion of patients who tested positive for anti-PF-
00547659 antibodies by visit (cumulative through week 12) was 
also assessed.
The β7+ central memory CD4+ T cells, defined as β7+ 
CD27+CD45RO+CD4+ lymphocytes,17 were measured by 
fluorescence-activated cell sorting (FACS) from blood samples 
taken at baseline, week 8 and week 12. Soluble MAdCAM was 
measured at baseline and week 12. (Details of flow cytometry 
methods are provided in the online supplementary text.) The 
FACS parameters were log transformed and analysed using 
a linear mixed model, with change from baseline as response; 
treatment, anti-TNF experience, concomitant immunosuppres-
sive therapy, baseline (log transformed), visit and treatment by 
visit interaction as fixed effects and patients as random effects.
Determination of sample size was based on an assumed CDAI 
response rate of 35% for the placebo group and 60% for at least 
one PF-00547659 dose at either week 8 or week 12. A study 
population of 240 (60 in each treatment group) was estimated 
to provide at least a 78% probability to detect a statistically 
significantly greater CDAI-70 response rate with PF-00547659 
compared with placebo.
Analyses of efficacy, biomarker and pharmacokinetic outcomes 
were based on findings from the modified intent-to treat popula-
tion, defined as all randomised patients who received at least one 
dose of investigational product.
resulTs
Patients’ disposition and baseline characteristics
Of 494 screened patients, 265 were eligible for study entry 
and randomised (figure 1): 64 patients to placebo and 68, 65 
and 68 patients to PF-00547659 22.5 mg, 75 mg and 225 mg, 
respectively. The most common reasons for patient ineligibility 
were failure to satisfy inclusion criteria for hsCRP concentration 
(71/229 (31%)), CDAI (24/229 (11%)) and ulcers on colonoscopy 
(17/229 (7%)). Three patients were randomised but not treated. 
(Details on patient disposition during the anti-TNF washout 
period and during the period between anti-TNF discontinuation 
and colonoscopy are provided in the online supplementary text.)
494 screened for eligibility  
265 underwent randomisation*
64 allocated to placebo* 
68 allocated to  
PF-0547659 22.5 mg* 
65 allocated to  
PF-0547659 75 mg* 
68 allocated to  
PF-0547659 225 mg 
58 completed treatment
  5 discontinued
  3 adverse events
     3 Crohn’s disease
  2 other     
54 completed treatment
  13 discontinued
    9 adverse events
      4 Crohn’s disease
      1 neutropaenia
      1 inflammatory mass
      1 abdominal pain
      1 liver abscess
      1 arthritis
    4 other          
52 completed treatment
  12 discontinued
    8 adverse events
      3 Crohn’s disease
      1 intestinal obstruction
      1 small intestinal obstruction
      1 arthralgia
      1 fistula
      1 cerebellar infarction
    4 other           
63 completed treatment
   5 discontinued
     4 adverse events
       2 Crohn’s disease
       1 small intestinal obstruction
       1 lung disorder
   1 other        
Figure 1 Disposition of patients. *Three patients were randomised but did not receive treatment (placebo, n=1; PF-0547659 22.5 mg, n=1; PF-
0547659, 75 mg, n=1).
group.bmj.com on November 15, 2017 - Published by http://gut.bmj.com/Downloaded from 
4 Sandborn WJ, et al. Gut 2017;0:1–12. doi:10.1136/gutjnl-2016-313457
Inflammatory bowel disease
Treated patients had a mean age of 35.5 years and a mean 
CDAI total baseline score of 315.3 (standard deviastion (SD), 
65.2). As shown in table 1, treatment groups were similar with 
respect to age, race, weight, fistulising disease, prior anti-TNF-α 
exposure, concomitant immunosuppressive therapies and CDAI 
score at baseline. Of the 262 patients who received treatment, 
227 (87%) completed the week 12 study visit. The majority had 
been treated previously with anti-TNF-α therapies (95%) and 
were not receiving concomitant immunosuppressive treatment 
(61%) at the time of randomisation. Only 13 (5%) patients were 
anti-TNF-α-naïve, all of whom were intolerant to or had failed 
immunosuppressive therapy. Twenty (8%) patients had their last 
dose of anti-TNF therapy within 8 weeks of treatment; 59 (23%) 
had their last dose within 12 weeks of treatment. Distribution 
of prior anti-TNF experience (failure vs intolerance) was similar 
among groups, as was prior treatment with immunosuppressive 
agents.
Primary endpoint
The proportions of patients who achieved a CDAI-70 response 
over time in the four treatment groups are shown in figure 2. At 
week 8, 47.7% of patients in the placebo group had a CDAI-70 
response versus 52.7%, 60.1% and 62.7% of patients in the 
PF-00547659 22.5 mg, 75 mg and 225 mg groups, respectively. 
Corresponding proportions of CDAI-70 responders at week 12 
were 58.6% in the placebo group and 62.0%, 64.7% and 57.5% 
in the PF-00547659 22.5 mg, 75 mg and 225 mg groups. The 
Hochberg-adjusted p values showed no significant difference 
between placebo and any dose of PF-00547659 at either week 
8 or 12.
secondary endpoints
Efficacy analyses for the key secondary endpoints supported the 
findings of the primary endpoint analysis (table 2). At week 8, 
Table 1 Baseline characteristics
PF-00547659
Placebo(n=63) 22.5 mg (n=66) 75 mg (n=65) 225 mg (n=68)
Age (years), mean (SD) 34.4 (11.1) 37.3 (13.0) 34.4. (10.7) 35.9 (11.0)
Females, n (%) 30 (47.6) 48 (72.7) 35 (53.8) 43 (63.2)
Race, n (%)
  White 54 (85.7) 53 (80.3) 53 (81.5) 60 (88.2)
  Black 1 (1.6) 2 (3.0) 2 (3.1) 2 (2.9)
  Asian 5 (7.9) 8 (12.1) 8 (12.3) 6 (8.8)
  Other 3 (4.8) 3 (4.5) 2 (3.1) 0
Weight (kg), mean (SD) 70.1 (19.4) 71.9 (17.5) 69.5 (21.5) 69.6 (20.9)
Smoking status, n (%)
  Never smoked 29 (46.0) 26 (39.4) 29 (44.6) 32 (47.1)
  Ex-smoker 15 (23.8) 18 (27.3) 15 (23.1) 15 (22.1)
  Smoker 19 (30.2) 22 (33.3) 21 (32.3) 21 (30.9)
Disease duration, years, mean 11.5 12.7 11.4 12.0
SES-CD total score* (severity), mean (SD) 19.3 (11.1) 19.1 (9.0) 17.4 (8.8) 15.7 (9.0)
Site of colonoscopic abnormality, n (%)
  Ileum 40 (63.5) 38 (57.6) 40 (61.5) 43 (63.2)
  Right colon 40 (63.5) 34 (51.5) 36 (55.4) 25 (36.8)
  Transverse colon 36 (57.1) 37 (56.1) 34 (52.3) 27 (39.7)
  Left colon 43 (68.3) 49 (74.2) 45 (69.2) 42 (61.8)
  Rectum 41 (61.5) 49 (74.2) 40 (61.5) 44 (64.7)
Fistulising disease, n (%) 14 (22.2) 15 (22.7) 19 (29.2) 15 (22.1)
hsCRP* (mg/L), median (range) 18.9 (2.3–240.9) 21.1 (1.3–178.0) 14.6 (0.3–180.1) 17.2 (2.4–117.3)
Faecal calprotectin* (µg/g), median (range) 1797 (179–27,545) 1705 (97–18,323) 1389 (23–10,977) 1346 (134–31,588)
Central memory CD4+T cells MESF, median (range) 638.5 (117–2647) 670.0 (45–1669) 877.5 (260–2402) 660.5 (193–2252)
CDAI score*, mean (SD) 313.1 (61.4) 307.4 (71.1) 324.1 (63.1) 316.4 (64.6)
Prior treatment strata, n (%)
  Relapsed after ≥1 anti-TNF-α 34 (54.0) 34 (51.5) 37 (56.9) 39 (57.4)
  No response to ≥1 anti-TNF-α 12 (19.0) 13 (19.7) 11 (16.9) 11 (16.2)
  Intolerant to ≥1 anti-TNF-α 12 (19.0) 13 (19.7) 12 (18.5) 13 (19.1)
  Failure/intolerance to any IS 5 (7.9) 6 (9.1) 5 (7.7) 5 (7.4)
Current use of IS therapy, n (%)
  Azathioprine 13 (20.6) 11 (16.7) 15 (23.1) 15 (22.1)
  6-Mercaptopurine 2 (3.2) 6 (9.1) 6 (9.2) 4 (5.9)
  Methotrexate 6 (9.5) 10 (15.2) 7 (10.8) 7 (10.3)
  No IS therapy 42 (66.7) 39 (59.1) 37 (56.9) 42 (61.8)
Current use of steroids, n (%) 29 (46.0) 31 (47.0) 36 (55.4) 35 (51.5)
*Data not available from all patients; therefore, n values may be smaller than for the total population.
CDAI, Crohn’s Disease Activity Index; hsCRP, high-sensitivity C reactive protein; IS, immunosuppressive; MESF, molecules of equivalent soluble fluorochrome; SD, standard 
deviation; SES-CD, Simple Endoscopic Activity Score; TNF, tumour necrosis factor.
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41.4% of patients who received placebo compared with 50.5%, 
48.3% and 57.0% of those who received PF-00547659 22.5 mg, 
75 mg and 225 mg, respectively, achieved a CDAI-100 response. 
Corresponding proportions of CDAI-100 responders at week 12 
were 44.4%, 56.0%, 47.7% and 53.8%.
CDAI remission was achieved at week 8 in 16.7% of patients 
in the placebo group compared with 29.1%, 23.8% and 26.9% 
of those in the PF-00547659 22.5 mg, 75 mg and 225 mg groups, 
respectively. At week 12, 23.0%, 26.8%, 28.5% and 29.6% of 
patients in these respective groups were in remission.
Although greater proportions of patients in all of the 
PF-00547659 dose groups achieved a CDAI-100 response and 
remission than in the placebo group, the differences between 
placebo and each of the PF-00547659 doses at week 8 and week 
12 were not statistically significant. Change in CDAI from base-
line, analysed using the mixed-effect repeated measures model, 


































































Week 8 Week 12
hsCRP  >18.8 mg/L
Week 8 Week 12
SES-CD >10 
Week 8
n=51 n=40 n=45 n=56 n=49 n=41 n=41 n=54 n=28 n=26 n=25 n=32 n=26 n=24 n=24 n=31
n=41 n=38 n=38 n=41 n=39 n=38 n=32 n=39 n=28 n=25 n=25 n=24 n=26 n=25 n=21 n=23
Week 12
SES-CD >17








Placebo          PF-0547659 22.5 mg          PF-0547659 75 mg          PF-0547659 225 mg
Figure 3 Proportions of patients who achieved CDAI remission (90% CI) with PF-00547659 22.5 mg, 75 mg and 225 mg versus placebo in subgroups 
with baseline median hsCRP concentration of (A) >5 mg/L and (B) >18.8 mg/L and with baseline median SES-CD of (C) >10 (25th percentile) and 
(D) >17. *p<0.05, PF-00547659 versus placebo. CDAI-70, Crohn’s Disease Activity Index; hsCRP, high-sensitivity C reactive protein; SES-CD, Simple 
Endoscopic Activity Score–Crohn’s Disease.
Figure 2 Proportions of patients who achieved a CDAI-70 response 
(90% CI) with PF-00547659 22.5 mg, 75 mg and 225 mg versus placebo 
at week 8 and week 12, modified intention-to-treat group. CDAI-70, 
Crohn’s Disease Activity Index 70-point decrease from baseline.
Table 2 Proportions of patients who achieved a CDAI-100 response 
and CDAI remission at week 8 and week 12
PF-00547659
Placebo 22.5 mg 75 mg 225 mg
CDAI-100 response
Week 8
  N 56 50 55 62
  Patients, % 41.4 50.5 48.3 57.0
  90% CI –11.3 to 29.5 –13.0 to 26.8 –3.6 to 34.8
Week 12
  N 54 51 49 61
  Patients, % 44.4 56.0 47.7 53.8
  90% CI –8.7 to 31.9 –17.3 to 24.0 –10.1 to 29.1
CDAI remission
Week 8
  N 57 50 56 62
  Patients, % 16.7 29.1 23.8 26.9
  90% CI –5.2 to 29.9 –9.2 to 23.4 –6.2 to 26.6
Week 12
  N 55 51 49 61
  Patients, % 23.0 26.8 28.5 29.6
  90% CI –14.6 to 22.2 –13.6 to 24.6 –11.6 to 24.8
CDAI, Crohn’s Disease Activity Index.
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Posthoc analyses
In analyses of CDAI-70 response, no treatment effects were 
observed at week 8 or week 12 in subgroups of patients with base-
line hsCRP >5 mg/L or >18.8 mg/L. The proportions of patients 
who achieved CDAI remission were greater in all PF-00547659 
dose groups than in the placebo group at both weeks 8 and 12 
in both hsCRP subgroups, but the between-group differences did 
not reach statistical significance (figure 3). Although treatment 
effects were not seen in analyses of CDAI-70 response at either 
time point in subgroups of patients with SES-CD >10 or >17, 
significant differences in the proportions of patients achieving 
CDAI remission were observed at both weeks 8 and 12 in 
patients with baseline SES-CD >17 who received 75 mg and 
225 mg of PF-0547659 (figure 3).
Exclusion of patients who had their last dose of anti-TNF 
therapy within 12 weeks of randomisation did not affect find-
ings of the analyses of response or remission.
biomarker endpoints
Faecal calprotectin concentrations varied widely across groups at 
baseline (table 1). Geometric mean per cent change from base-
line in faecal calprotectin concentrations was reduced by week 8 
in all active dose groups; concentrations continued to decline in 
the PF-00547659 22.5 mg and 75 mg groups but increased in the 
225 mg group (online supplementary figure S1). Concentrations 
from baseline were also reduced in the placebo group at week 
4 but increased by week 8 and remained stable at week 12. At 
week 12, reductions (geometric mean) of 6.5%, 36.4%, 29.4% 
Figure 4 Relative ratios of α4β7+ central memory CD4+T cells as (A) percentage of overall CD4+expressing cells, (B) absolute number (cells/µL) and 
(C) MESF for PF-00547659 22.5 mg, 75 mg and 225 mg versus placebo. MESF, molecules of equivalent soluble fluorochrome.
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and 10.5% were observed in the placebo and PF-00547659 
22.5 mg, 75 mg and 225 mg groups, respectively.
Serum hsCRP concentrations markedly declined from base-
line in all three PF-00547659 groups at week 4, continued to 
decline in the 22.5 mg and 75 mg groups and remained stable 
in the 225 mg group at week 12 (online supplementary figure 
S2). Concentrations of hsCRP in the placebo group also declined 
from baseline to week 4 but subsequently increased between 
week 8 and week 12. At week 12, a 5.6% increase (geometric 
mean) from baseline in hsCRP concentration was observed in 
the placebo group compared with reductions of 30.9%, 21.8% 
and 20.0% in the 22.5 mg, 75 mg and 225 mg PF-00547659 
groups, respectively.
Circulating β7+ central memory CD4+ T cells increased in 
a dose-dependent manner at week 8 in PF-00547659-treated 
patients; they also increased at week 12 but not dose-de-
pendently. At week 8, the increases of β7 + cells as a percentage 
of overall CD4+ expressing cells were 1.21-fold, 1.22-fold 
and 1.34-fold in the 22.5 mg, 75 mg and 225 mg PF-00547659 
groups, respectively, compared with placebo (figure 4A); corre-
sponding values after 12 weeks of PF-00547659 were 1.20, 
1.32 and 1.27. These changes for per cent β7+ central memory 
T cell estimates were statistically significant for all doses at 
weeks 8 and 12. At week 8, the relative ratios of molecules of 
equivalent soluble fluorochrome (MESF), the unit measure of 
β7+ protein expression on central memory Tcells, to placebo 
for PF-00547659 22.5 mg, 75 mg and 225 mg were 1.63, 1.73 
and 1.73, respectively (figure 4C); corresponding values after 
12 weeks were 1.68, 1.52 and 1.48. Increases in the abso-
lute number of β7+ central memory T cells (figure 4B) and 
in MESF (figure 4C) were also statistically significant for all 
doses of PF-00547659 compared with placebo at weeks 8 and 
12.
Soluble MAdCAM concentrations in PF-00547659- but not 
placebo-treated patients decreased significantly, in a dose-related 
manner, at week 2 compared with baseline and remained low 
during the study. After 12 weeks, median suppression of soluble 
MAdCAM of 88.7%, 96.5% and 97.8% was observed following 
monthly dosing of 22.5 mg, 75 mg and 225 mg, respectively, 
whereas a median increase of 6.7% was seen with placebo.
Pharmacokinetics and ADA
Findings from intensive pharmacokinetic sampling in 30 patients 
are presented in table 3. Further analyses showed no concentra-
tion-effect relationship for the central memory T cells, as the 
increase in β7+ cells in the blood was similar across all phar-
macokinetic quartiles (figure 5). No relationship was found 
between hsCRP or faecal calprotectin and trough concentra-
tion of PF-00547659 (figure 6A and B). CDAI-70 and CDAI-
100 response and remission were poorly correlated with 
PF-00547659 trough concentrations (figure 7A and B).
A total of 588 of 618 (95%) samples from 190 patients on 
active treatment were reported negative for ADA. Overall, 5% 
of patients were confirmed to be ADA positive, with antibody 
titres generally low and close to the cut-off (4.64; none were 
higher than 9.3). In patients with postbaseline confirmatory 
ADA (n=15), ADA positivity did not have an obvious effect on 
Table 3 Pharmacokinetic parameters (n=30)
PF-00547659
22.5 mg 75 mg 225 mg
AUC0-648 µg hour/mL 558 3920 11 100
Cmax µg/mL (median) 2.03 11.0 30.6
AUC0-648, area under the serum concentration–time curve from 0 to 248 hours; Cmax, 
maximum serum concentration.
Figure 5 Median percentage of changes from baseline in MESF of β7+ cells after PD-00547659 treatment across pharmacokinetic quartiles. MESF, 
molecules of equivalent soluble fluorochrome.
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exposure, CDAI scores or the safety profile. (Additional details 
of ADA analysis are provided in the online supplementary text.)
safety
Overall, the incidence of AEs, serious AEs (SAEs) and discon-
tinuations was similar across treatment groups (table 4 and 
online supplementary table S1). No evidence was seen of a 
safety signal or an increased incidence of AEs at higher doses 
of PF-00547659.
SAEs were reported more frequently in patients receiving 
PF-00547659 versus placebo, with no evidence of a dose 
response (table 3). Most SAEs were due to or related to CD 
(n=5, n=6, n=7 and n=8 in the placebo vs 22.5 mg, 75 mg and 
225 mg treatment groups, respectively). Reported SAEs were 
considered unlikely to be due to the study drug. Injection site 
reactions—reported as bruising, erythema, pain and swelling—
were uncommon and occurred at similar rates in the placebo and 
PF-00547659 groups.
During the 12-week study period, among the 35 patients who 
discontinued treatment, 24 withdrew due to AEs. More discon-
tinuations were observed in the 22.5 mg (n=13) and 75 mg 
(n=12) PF-00547659 treatment groups compared with the 
Figure 6 Systemic exposure–response relationship between PD-00547659 at week 12 (by dose) and inflammation measured by (A) hsCRP or (B) 
faecal calprotectin. Data for two patients with a percentage change from baseline in hsCRP >2000 are not shown in (A) to allow clearer presentation 
of the other points; data for one patient with a percentage change from baseline in faecal calprotectin >1000 are also not shown in (B) for this 
reason. In addition, data are not included for patients in the placebo group and patients in the active treatment groups with no pharmacokinetic 
information. hsCRP, high-sensitivity C reactive protein.
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placebo and 225 mg PF-00547659 groups (n=5 each) (figure 1). 
Withdrawals due to AEs were also higher in the 22.5 mg and 
75 mg PF-00547659 groups (n=9 and n=8, respectively) than 
in the placebo and 225 mg PF-00547659 groups (n=3 and 
n=4, respectively). Most AE withdrawals were due to CD or its 
complications. No evidence was seen of a PF-00547659 drug or 
dose relationship.
Figure 7 Proportions of patients who achieved (A) CDAI-70 and (B) CDAI-100 responses by quartile of exposure at week 12. CDAI-70/CDAI-100, 
Crohn’s Disease Activity Index 70/100-point decrease from baseline.
Table 4 Incidence of AEs
PF-00547659
Placebo (n=63) 22.5 mg (n=66) 75 mg (n=65) 225 mg (n=68)
Number of AEs 141 175 192 190
Patients with AEs, n (%) 54 (85.7) 57 (86.4) 51 (78.5) 54 (79.4)
Patients with SAEs, (%) 5 (7.9) 11 (16.7) 9 (13.8) 11 (16.2)
Patients who discontinued due to AEs, n (%) 3 (4.8) 9 (13.6) 8 (12.3) 4 (5.9)
Patients with dose reduction or temporary discontinuation due to AEs, n (%) 0 2 (3.0) 3 (4.6) 2 (2.9)
AE, adverse event; SAE, serious adverse event.
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DIsCussIOn
The differences in the rates of CDAI-70 response, CDAI-100 
response and CDAI remission between PF-00547659 and 
placebo were not statistically significant at weeks 8 or 12 in 
patients with moderately-to-severely active CD, 95% of whom 
had previously failed or were intolerant to anti-TNF therapy. 
However, subgroup analyses for the more rigorous endpoint 
of CDAI remission did show a significant treatment effect for 
PF-00547659 in patients with a baseline hsCRP concentra-
tion >5 mg/L or >18.8 mg/L (median) and in those with baseline 
SES-CD >17.
A placebo effect in response and remission that rises quickly to 
a high level has been described previously in patients with CD.18 
Factors that are associated with lower placebo-effect response 
and remission rates are objective evidence of inflammation at 
baseline (ie, elevated hsCRP and/or faecal calprotectin and/or 
presence of ulcers at colonoscopy)6 19–22 and prior anti-TNF 
therapy.6 7 23 Placebo remission rates in the latter patient popu-
lation have been reported to range from 5% to 10%. In this 
study, patients were required to have a baseline hsCRP concen-
tration >3 mg/L at screening, and ulcers present at a colonos-
copy performed and interpreted at the local site within 8 weeks 
of screening or during screening. Although the study included 
patients who had failed immunosuppressive therapy, they 
comprised only 5% of the study population, with the remaining 
95% of patients having failed or been intolerant to anti-TNF 
therapy. Thus, the high placebo-treatment response and remis-
sion rates observed in our study are highly unexpected and not 
easily explained.
Phase II studies of a similar size to the current study were 
conducted to evaluate two other anti-integrin agents, natal-
izumab24 and vedolizumab.25 Although these studies are not 
directly comparable to the current study of PF-00547659 
because of differences in populations studied and timing 
of endpoints, like the current study, they reported both 
CDAI-70 and remission endpoints. The outcome at week 8 
was not the primary endpoint in any of the studies, but it is 
the only time point reported in all three studies. At 8 weeks, 
similar proportions of patients receiving the lowest evalu-
ated dose of the three agents achieved a CDAI-70 response 
(PF-00547659 22.5 mg, 53%; natalizumab 3 mg/kg, 56%; 
and vedolizumab 0.5 mg/kg, 49%), but the proportion of 
patients who received placebo and achieved this endpoint in 
the present study was considerably higher (48%) than that 
in the natalizumab (35%) and vedolizumab (41%) studies. 
In contrast, the proportions of patients in the placebo group 
who achieved remission at week 8 were similar in the three 
studies (17%, 16% and 21%, respectively), but the propor-
tion of patients receiving the highest dose of PF-00547659 
who achieved remission (27%) was paradoxically lower than 
that achieving remission with the highest dose of natali-
zumab (43%) and vedolizumab (37%).
One design element of this trial that differs from that 
of previous studies is that the required washout period for 
previous anti-TNF therapy was 6 weeks, rather than 8 weeks, 
prior to baseline. Theoretically, the prior anti-TNF anti-
body may still have been present in the systemic circulation 
following recent anti-TNF treatment, creating a carryover 
effect; a similar observation was made previously in patients 
with CD treated with adalimumab who had previously failed 
infliximab but still had infliximab in the circulation.6 Dura-
tion of the study period may also have been a factor in the 
high placebo effect. In a meta-analysis of 23 randomised 
controlled trials in active CD, the most important factor 
contributing to the CDAI remission rate among place-
bo-treated patients appeared to be length of the study; esti-
mated remission rates were 12% for studies <2 months, 19% 
for studies ≥2 to 4 months and 32% for studies ≥4 months in 
duration.18 The higher rate observed at 12 weeks compared 
with 8 weeks in the current study seems to be consistent with 
these findings. This effect also appeared to be pronounced in 
the subgroup analyses assessing remission rates at different 
baseline hsCRP levels. Another possible contributing factor 
may have been that the baseline colonoscopy examinations 
were not centrally read by a blinded central reader, a clin-
ical trial design feature that has been associated with higher 
placebo response and remission rates in patients with ulcer-
ative colitis.26 The relative overrepresentation of patients 
who had failed anti-TNF therapy (73% vs 27% who had not 
failed, including only 8% who were anti-TNF–naïve) should 
also be noted. In contrast, 48% of patients with CD treated 
with vedolizumab had failed anti-TNF therapy, and among 
them the difference in remission rates between active and 
placebo groups was 6%, whereas the difference in CDAI-
100 response rates was 1%.6 Finally, the use of CDAI as an 
entry criterion and as an endpoint, while common to studies 
of CD, raises the possibility of regression to the mean as a 
confounder.
The unexpectedly high rates of response and remission in 
patients receiving placebo ultimately render this trial a technical 
failure. We are unable to determine with certainty whether the 
trial failed because the high placebo rates impeded detection 
of a treatment difference or the drug simply was not effective. 
Findings of subgroup analyses suggest potential clinical bene-
fits of treatment with PF-00547659, as significant differences 
between placebo and active treatment were seen in patients with 
higher levels of inflammation, measured by baseline hsCRP, or 
more active disease, measured by SES-CD. These findings need 
to be corroborated in a prospective study, but they suggest that 
PF-00547659 may be an effective treatment for CD, and that 
the failure of the trial was due to unknown technical factors that 
resulted in an unexpectedly high response rate in patients who 
received placebo, rather than lack of efficacy.
Although the primary endpoint was not met, PF-00547659 
was pharmacologically active, as shown by a dose-related 
increase in circulating β7+ central memory T cells and a 
sustained dose-related decrease in soluble MAdCAM. The 
increase in circulating lymphocytes in PF-00547659-treated 
patients observed in this and earlier studies27 28 may repre-
sent a reduction of MAdCAM/integrin-mediated migration 
of lymphocytes to the gut, resulting in increased numbers 
of central memory T cells in the blood circulation. In future 
trials, these biomarkers should be further evaluated as 
potential markers for drug exposure that may be directly 
correlated with clinical efficacy. Due to the elevated hsCRP 
entry criterion (>3 mg/L), mean values in all groups were 
elevated at baseline. The geometric mean values for patients 
in the treatment arms remained below baseline for all post-
baseline time points, but by week 12 the geometric mean for 
placebo-treated patients had increased above the baseline.
The three dose levels of PF-00547659 all appeared to be 
safe and well tolerated in this population. Most common 
AEs were related to the underlying disease, with no evidence 
of a dose response in any AE group. This safety profile needs 
to be interpreted with some caution, as a larger number of 
patients and a longer duration of therapy will be required to 
fully assess the safety of PF-00547659 in patients with CD.
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In conclusion, although prospective efficacy endpoints 
were not met in this study, signals of robust pharmacological 
activity based on circulating soluble MAdCAM and increased 
circulating β7+ central memory T cells were observed. The 
placebo clinical response and remission rates were higher 
than expected, making assessment of efficacy difficult. 
Nonetheless, posthoc analyses showed evidence of efficacy 
in patients with greater endoscopic or biomarker signals of 
active inflammation.
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